NASDAQ:ADVM - Adverum Biotechnologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.15 0.00 (0.00 %)
(As of 05/27/2018 01:25 AM ET)
Previous Close$6.15
Today's Range$6.0750 - $6.20
52-Week Range$2.40 - $8.59
Volume238,340 shs
Average Volume728,192 shs
Market Capitalization$382.97 million
P/E Ratio-4.77
Dividend YieldN/A
Beta3.64

About Adverum Biotechnologies (NASDAQ:ADVM)

Adverum Biotechnologies logoAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-272-6269

Debt

Debt-to-Equity RatioN/A
Current Ratio26.88
Quick Ratio26.88

Price-To-Earnings

Trailing P/E Ratio-4.77
Forward P/E Ratio-4.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.85 million
Price / Sales207.01
Cash FlowN/A
Price / CashN/A
Book Value$3.95 per share
Price / Book1.56

Profitability

EPS (Most Recent Fiscal Year)($1.29)
Net Income$-56,140,000.00
Net Margins-3,571.30%
Return on Equity-28.51%
Return on Assets-26.45%

Miscellaneous

Employees78
Outstanding Shares62,270,000

Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies (NASDAQ:ADVM) announced its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.30) EPS for the quarter, missing the Zacks' consensus estimate of ($0.29) by $0.01. The biotechnology company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.40 million. Adverum Biotechnologies had a negative net margin of 3,571.30% and a negative return on equity of 28.51%. View Adverum Biotechnologies' Earnings History.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Adverum Biotechnologies.

What price target have analysts set for ADVM?

3 brokerages have issued 1 year price targets for Adverum Biotechnologies' stock. Their forecasts range from $3.50 to $12.00. On average, they expect Adverum Biotechnologies' stock price to reach $7.1667 in the next year. View Analyst Ratings for Adverum Biotechnologies.

What are Wall Street analysts saying about Adverum Biotechnologies stock?

Here are some recent quotes from research analysts about Adverum Biotechnologies stock:
  • 1. According to Zacks Investment Research, "Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California. " (5/22/2018)
  • 2. Chardan Capital analysts commented, "We note PRVs have in 2017 sold for: 1) $130 mm to Ultragenyx Pharmaceutical (unrated), announced 18 December 2017; 2) $125 mm to BioMarin Pharmaceutical (unrated), announced 27 November 2017, and 3) $125 mm to Sarepta Therapeutics (unrated), announced 21 February 2017. We understand Spark will announce the pricing of Luxturna in January, and that the drug will be available in late 1Q18. The Midwest CEPAC will convene to discuss the Institute for Clinical and Economic Review (ICER) document on Luxturna, on 25 January 2018. Luxturna’s approval is an important (+) for GT, particularly for AAV-based ophthalmology companies. We understand Luxturna is the first gene therapy approved in the US for a genetic disease, the first in vivo and AAV-based gene therapy approved in the US, and the first pharmacologic treatment approved for an inherited retinal disease (IRD)." (12/19/2017)

Who are some of Adverum Biotechnologies' key competitors?

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the folowing people:
  • Mr. Paul B. Cleveland, Chairman (Age 61)
  • Dr. Amber Salzman Ph.D., Chief Exec. Officer, Pres and Director (Age 56)
  • Dr. Mitchell H. Finer Ph.D., Co-Founder and Director (Age 59)
  • Dr. Mehdi Gasmi Ph.D., Chief Science and Technology Officer (Age 51)
  • Ms. Leone D. Patterson, Chief Financial Officer (Age 55)

Has Adverum Biotechnologies been receiving favorable news coverage?

Headlines about ADVM stock have trended positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adverum Biotechnologies earned a coverage optimism score of 0.31 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 46.43 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (3.21%), Millennium Management LLC (2.68%), Alkeon Capital Management LLC (2.40%), Dimensional Fund Advisors LP (1.89%), Rock Springs Capital Management LP (1.45%) and BlackRock Inc. (1.11%). View Institutional Ownership Trends for Adverum Biotechnologies.

Which institutional investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Russell Investments Group Ltd.. View Insider Buying and Selling for Adverum Biotechnologies.

Which institutional investors are buying Adverum Biotechnologies stock?

ADVM stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Alkeon Capital Management LLC, Millennium Management LLC, Rock Springs Capital Management LP, Nexthera Capital LP, Artal Group S.A., BlackRock Inc. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Adverum Biotechnologies.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $6.15.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $382.97 million and generates $1.85 million in revenue each year. The biotechnology company earns $-56,140,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Adverum Biotechnologies employs 78 workers across the globe.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]


MarketBeat Community Rating for Adverum Biotechnologies (ADVM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Adverum Biotechnologies (NASDAQ:ADVM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Adverum Biotechnologies in the last 12 months. Their average twelve-month price target is $7.1667, suggesting that the stock has a possible upside of 16.53%. The high price target for ADVM is $12.00 and the low price target for ADVM is $3.50. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.1667$7.1667$7.1667$4.75
Price Target Upside: 16.53% upside10.26% upside10.26% upside31.94% upside

Adverum Biotechnologies (NASDAQ:ADVM) Consensus Price Target History

Price Target History for Adverum Biotechnologies (NASDAQ:ADVM)

Adverum Biotechnologies (NASDAQ:ADVM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2018Piper Jaffray CompaniesInitiated CoverageBuy$12.00MediumView Rating Details
12/19/2017Chardan CapitalReiterated RatingHoldLowView Rating Details
10/12/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$6.00N/AView Rating Details
8/10/2016Jefferies GroupReiterated RatingBuy$12.00N/AView Rating Details
5/27/2016CowenInitiated CoverageOutperformN/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Adverum Biotechnologies (NASDAQ:ADVM) Earnings History and Estimates Chart

Earnings by Quarter for Adverum Biotechnologies (NASDAQ:ADVM)

Adverum Biotechnologies (NASDAQ:ADVM) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.3 EPS
Next Year EPS Consensus Estimate: $-1.34 EPS

Adverum Biotechnologies (NASDAQ ADVM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.30)N/AView Earnings Details
5/9/2018Q1($0.29)($0.30)$0.40 million$0.22 millionViewN/AView Earnings Details
3/6/2018Q4 2017($0.35)($0.32)$0.46 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.29)($0.32)$0.46 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.37)($0.27)$0.46 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.26)($0.38)$0.46 millionViewN/AView Earnings Details
3/6/2017Q4($0.30)($0.54)$0.49 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.29)($0.35)$0.40 millionViewN/AView Earnings Details
8/9/2016Q2 2016($0.38)($0.36)$0.31 millionViewN/AView Earnings Details
5/6/2016Q116($0.39)($0.57)$0.27 millionViewN/AView Earnings Details
3/3/2016Q4($0.40)($0.45)$0.20 million$0.96 millionViewN/AView Earnings Details
11/9/2015Q3 2015($0.42)($0.55)$0.20 million$0.95 millionViewN/AView Earnings Details
8/13/2015Q215($0.37)($0.38)$0.20 million$0.20 millionViewN/AView Earnings Details
5/13/2015Q1 2015($0.42)($0.38)$0.14 million$0.20 millionViewN/AView Earnings Details
3/5/2015Q4 2014($0.33)($0.46)$0.20 million$0.20 millionViewN/AView Earnings Details
11/12/2014Q3 2014($0.15)($0.50)$0.03 million$0.20 millionViewN/AView Earnings Details
9/11/2014Q2 2014($0.51)($2.27)$0.14 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Adverum Biotechnologies (NASDAQ:ADVM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Adverum Biotechnologies (NASDAQ ADVM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 51.36%
Insider Trading History for Adverum Biotechnologies (NASDAQ:ADVM)
Institutional Ownership by Quarter for Adverum Biotechnologies (NASDAQ:ADVM)

Adverum Biotechnologies (NASDAQ ADVM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/8/2015Mehdi GasmiVPSell500$38.64$19,320.00View SEC Filing  
6/8/2015Paul WachterDirectorSell1,192$38.64$46,058.88View SEC Filing  
5/26/2015Paul WachterDirectorSell1,192$36.94$44,032.48View SEC Filing  
5/22/2015Steven Daniel SchwartzDirectorSell16,875$38.38$647,662.50View SEC Filing  
5/13/2015Linda BainCFOSell285$34.94$9,957.90View SEC Filing  
5/13/2015Mark S BlumenkranzDirectorSell715$34.94$24,982.10View SEC Filing  
5/8/2015Steven Daniel SchwartzDirectorSell17,250$33.05$570,112.50View SEC Filing  
4/28/2015Mehdi GasmiVPSell1,000$35.67$35,670.00View SEC Filing  
4/27/2015Paul WachterDirectorSell1,192$35.61$42,447.12View SEC Filing  
4/23/2015Steven Daniel SchwartzDirectorSell16,875$38.62$651,712.50View SEC Filing  
4/21/2015Mehdi GasmiVPSell1,000$39.21$39,210.00View SEC Filing  
4/20/2015Paul WachterDirectorSell1,192$40.19$47,906.48View SEC Filing  
4/16/2015Mark S BlumenkranzDirectorSell25,000$41.59$1,039,750.00View SEC Filing  
4/14/2015Zygtech, LlcMajor ShareholderSell25,000$39.55$988,750.00View SEC Filing  
4/13/2015Paul WachterDirectorSell1,192$39.34$46,893.28View SEC Filing  
4/9/2015Steven Daniel SchwartzDirectorSell17,250$39.73$685,342.50View SEC Filing  
4/7/2015Hans HullSVPSell27,500$38.60$1,061,500.00View SEC Filing  
4/7/2015Mehdi GasmiVPSell9,000$38.60$347,400.00View SEC Filing  
8/5/2014James E FlynnInsiderBuy1,334,467$23.92$31,920,450.64View SEC Filing  
8/5/2014Regeneron Pharmaceuticals IncMajor ShareholderBuy588,235$17.00$9,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Adverum Biotechnologies (NASDAQ ADVM) News Headlines

Source:
DateHeadline
Adverum Biotechnologies (ADVM) Given Average Rating of "Buy" by BrokeragesAdverum Biotechnologies (ADVM) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 24 at 3:46 AM
Adverum Biotechnologies Presents Additional Long-term Preclinical Data on ADVM-022 in Wet AMD at ASGCT 21st ...Adverum Biotechnologies Presents Additional Long-term Preclinical Data on ADVM-022 in Wet AMD at ASGCT 21st ...
globenewswire.com - May 19 at 5:58 PM
Adverum Biotechnologies (ADVM) Highlights Additional Long-term Preclinical Data on ADVM-022 in Wet AMDAdverum Biotechnologies (ADVM) Highlights Additional Long-term Preclinical Data on ADVM-022 in Wet AMD
www.streetinsider.com - May 19 at 8:07 AM
Adverum Biotechnologies (ADVM) Coverage Initiated by Analysts at Piper JaffrayAdverum Biotechnologies (ADVM) Coverage Initiated by Analysts at Piper Jaffray
www.americanbankingnews.com - May 18 at 3:08 PM
Adverum Biotechnologies (ADVM) Raised to "Buy" at Zacks Investment ResearchAdverum Biotechnologies (ADVM) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 15 at 4:22 PM
Contrasting Adverum Biotechnologies (ADVM) & OXiGENE (MATN)Contrasting Adverum Biotechnologies (ADVM) & OXiGENE (MATN)
www.americanbankingnews.com - May 13 at 3:20 PM
Adverum Biotechnologies (ADVM) Announces  Earnings ResultsAdverum Biotechnologies (ADVM) Announces Earnings Results
www.americanbankingnews.com - May 10 at 4:46 PM
Adverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate UpdateAdverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 9 at 5:40 PM
Adverum Biotechnologies: 1Q Earnings SnapshotAdverum Biotechnologies: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:40 PM
What Are Analysts Saying About Adverum Biotechnologies Inc’s (NASDAQ:ADVM) Earnings Trajectory?What Are Analysts Saying About Adverum Biotechnologies Inc’s (NASDAQ:ADVM) Earnings Trajectory?
finance.yahoo.com - May 7 at 5:44 PM
The Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and AdverumThe Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and Adverum
finance.yahoo.com - May 7 at 8:14 AM
After-Hours Stock Movers 05/03: (CVGI) (VIAV) (SHAK) Higher; (FLR) (ANET) (TSRO) Lower (more...)After-Hours Stock Movers 05/03: (CVGI) (VIAV) (SHAK) Higher; (FLR) (ANET) (TSRO) Lower (more...)
www.streetinsider.com - May 4 at 5:40 PM
Here's Why Adverum Biotechnologies Got Crushed TodayHere's Why Adverum Biotechnologies Got Crushed Today
finance.yahoo.com - May 4 at 5:40 PM
ValuEngine Upgrades Adverum Biotechnologies (ADVM) to "Hold"ValuEngine Upgrades Adverum Biotechnologies (ADVM) to "Hold"
www.americanbankingnews.com - May 4 at 3:34 PM
Heres Why Adverum Biotechnologies Got Crushed TodayHere's Why Adverum Biotechnologies Got Crushed Today
www.fool.com - May 4 at 1:17 PM
Envision Healthcare (EVHC) to Report Q1 Earnings: Whats Up?Envision Healthcare (EVHC) to Report Q1 Earnings: What's Up?
www.zacks.com - May 4 at 8:14 AM
BRIEF-Adverum Biotechnologies Announces Leadership ChangesBRIEF-Adverum Biotechnologies Announces Leadership Changes
www.reuters.com - May 4 at 8:14 AM
Adverum Biotechnologies (ADVM) Reports L-T Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMDAdverum Biotechnologies (ADVM) Reports L-T Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD
www.streetinsider.com - May 3 at 5:30 PM
Adverum Biotechnologies (ADVM) CEO to Step DownAdverum Biotechnologies (ADVM) CEO to Step Down
www.streetinsider.com - May 3 at 5:30 PM
Adverum Biotechnologies Announces Leadership ChangesAdverum Biotechnologies Announces Leadership Changes
finance.yahoo.com - May 3 at 5:30 PM
BRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMDBRIEF-Adverum Biotechnologies Announces Long-Term Preclinical Efficacy Data On ADVM-022 Gene Therapy In Wet AMD
www.reuters.com - May 1 at 5:22 PM
Adverum Biotechnologies (ADVM) Scheduled to Post Earnings on MondayAdverum Biotechnologies (ADVM) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 8:35 AM
Adverum Biotechnologies (ADVM) Receives Consensus Recommendation of "Buy" from AnalystsAdverum Biotechnologies (ADVM) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 29 at 3:24 AM
Investors Buy Large Volume of Adverum Biotechnologies Call Options (ADVM)Investors Buy Large Volume of Adverum Biotechnologies Call Options (ADVM)
www.americanbankingnews.com - April 25 at 7:20 AM
Are Earnings Prospects Improving For Loss-Making Adverum Biotechnologies Inc’s (NASDAQ:ADVM)?Are Earnings Prospects Improving For Loss-Making Adverum Biotechnologies Inc’s (NASDAQ:ADVM)?
finance.yahoo.com - April 20 at 5:26 PM
Adverum Biotechnologies (ADVM) Expected to Announce Earnings of -$0.29 Per ShareAdverum Biotechnologies (ADVM) Expected to Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 15 at 3:15 PM
Adverum Biotechnologies (ADVM) Upgraded by BidaskClub to "Strong-Buy"Adverum Biotechnologies (ADVM) Upgraded by BidaskClub to "Strong-Buy"
www.americanbankingnews.com - April 12 at 10:47 AM
Adverum Biotechnologies (ADVM) Hold Rating Reiterated at Chardan CapitalAdverum Biotechnologies' (ADVM) Hold Rating Reiterated at Chardan Capital
www.americanbankingnews.com - April 9 at 1:19 PM
Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, ArsanisResearch Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis
www.nasdaq.com - April 9 at 8:12 AM
Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook — Fundamental Analysis, Calculating Forward MovementResearch Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - April 9 at 8:12 AM
Adverum Biotechnologies: Gene Therapy Company And Our New BuyAdverum Biotechnologies: Gene Therapy Company And Our New Buy
seekingalpha.com - April 8 at 9:25 AM
Adverum Biotechnologies Inc (ADVM) Given Consensus Rating of "Hold" by BrokeragesAdverum Biotechnologies Inc (ADVM) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 4 at 3:24 AM
Adverum Biotechnologies (ADVM) Rating Lowered to Strong Sell at ValuEngineAdverum Biotechnologies (ADVM) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 31 at 4:56 PM
Adverum Biotechnologies (ADVM) Lifted to "Hold" at Zacks Investment ResearchAdverum Biotechnologies (ADVM) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 9:36 PM
Zacks: Brokerages Expect Adverum Biotechnologies Inc (ADVM) to Post -$0.29 Earnings Per ShareZacks: Brokerages Expect Adverum Biotechnologies Inc (ADVM) to Post -$0.29 Earnings Per Share
www.americanbankingnews.com - March 29 at 7:24 PM
Adverum Biotechnologies (ADVM) Lowered to Hold at Zacks Investment ResearchAdverum Biotechnologies (ADVM) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 28 at 4:25 PM
4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End
finance.yahoo.com - March 27 at 8:20 AM
Adverum Biotechnologies (ADVM) Upgraded to Buy at Zacks Investment ResearchAdverum Biotechnologies (ADVM) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 23 at 4:34 PM
Adverum Biotechnologies (ADVM) Stock Rating Lowered by Zacks Investment ResearchAdverum Biotechnologies (ADVM) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 22 at 4:32 PM
Adverum Biotechnologies (ADVM) Cut to Hold at Zacks Investment ResearchAdverum Biotechnologies (ADVM) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 15 at 4:46 PM
Adverum: A Lot Done, A Lot More To Do - Seeking AlphaAdverum: A Lot Done, A Lot More To Do - Seeking Alpha
seekingalpha.com - March 15 at 8:10 AM
Adverum Biotechnologies (ADVM) Raised to Buy at Zacks Investment ResearchAdverum Biotechnologies (ADVM) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 14 at 5:32 PM
 Brokerages Expect Adverum Biotechnologies Inc (ADVM) Will Announce Earnings of -$0.31 Per Share Brokerages Expect Adverum Biotechnologies Inc (ADVM) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - March 12 at 3:55 PM
Adverum Biotechnologies (ADVM) Downgraded by BidaskClub to BuyAdverum Biotechnologies (ADVM) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - March 10 at 4:36 PM
Adverum Biotechnologies Inc (ADVM) Receives Average Recommendation of "Hold" from AnalystsAdverum Biotechnologies Inc (ADVM) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 10 at 4:14 AM
Adverum Biotechnologies (ADVM) Releases Quarterly  Earnings Results, Beats Estimates By $0.03 EPSAdverum Biotechnologies (ADVM) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - March 7 at 8:14 AM
Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:11 AM
Adverum Biotechnologies (ADVM) Presents At Raymond James 39th Annual Institutional Investors Conference - SlideshowAdverum Biotechnologies (ADVM) Presents At Raymond James 39th Annual Institutional Investors Conference - Slideshow
seekingalpha.com - March 6 at 5:44 PM
Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate UpdateAdverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 6 at 5:44 PM
Adverum Biotechnologies Inc (ADVM) Sees Large Increase in Short InterestAdverum Biotechnologies Inc (ADVM) Sees Large Increase in Short Interest
www.americanbankingnews.com - March 3 at 3:26 AM

SEC Filings

Adverum Biotechnologies (NASDAQ:ADVM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Adverum Biotechnologies (NASDAQ:ADVM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Adverum Biotechnologies (NASDAQ ADVM) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.